About | HeinOnline Law Journal Library | HeinOnline Law Journal Library | HeinOnline



H. Rept. 115-760,Part 1 1 (2018-06-19)

handle is hein.congrecreports/crptxaise0001 and id is 1 raw text is: AUTHENTICATED  r
U.S. GOVERNMENT
INFORMATION 4














                    115TH CONGRESS                                     REPT.115-760
                       2d Session  J  HOUSE   OF REPRESENTATIVES           Part 1







                       EXPANDING OVERSIGHT OF OPIOID PRESCRIBING AND
                                        PAYMENT ACT OF 2018




                     JUNE 19, 2018.-Committed to the Committee of the Whole House on the State of
                                       the Union and ordered to be printed




                      Mr.  BRADY  of Texas, from the Committee on Ways  and  Means,
                                         submitted  the following


                                             REPORT

                                           [To accompany H.R. 5723]

                              [Including cost estimate of the Congressional Budget Office]

                      The  Committee  on Ways   and Means,  to whom   was referred the
                    bill (H.R. 5723) to require the Medicare  Payment  Advisory  Com-
                    mission to report on opioid payment,  adverse incentives, and data
                    under  the Medicare  program, having  considered the  same, report
                    favorably thereon with an amendment   and recommend   that the bill
                    as amended  do pass.

                                                CONTENTS
                                                                                   Page
                     I. SUMMARY  AND BACKGROUND    .................................................................  2
                          A. Purpose and Sum m ary  .........................................................................  2
                          B. Background and Need for Legislation  ................................................  2
                          C . Legislative  H istory  ...............................................................................  3
                     II. EXPLANATION OF THE BILL .....................................................................  3
                          A. Expanding Oversight of Opioid Prescribing and Payment Act .........  3
                    III. VOTES OF THE COMM ITTEE .....................................................................  4
                    IV. BUDGET EFFECTS  OF THE BILL ...............................................................  4
                          A. Committee Estimate of Budgetary Effects ...................        4
                          B. Statement Regarding New Budget Authority and Tax Expendi-
                              tures Budget  Authority  ......................................................................  4
                           C. Cost Estimate Prepared by the Congressional Budget Office ...........  4
                     V. OTHER MATTERS  TO BE DISCUSSED  UNDER  THE  RULES OF THE
                         H O U SE   ..........................................................................................................  13
                         A.  Committee Oversight Findings and Recommendations ...........      13
                           B. Statement of General Performance Goals and Objectives ...............  13
                           C. Information Relating to Unfunded Mandates .................       13
                           D. Congressional Earmarks, Limited Tax Benefits, and Limited Tariff
                              B en efits  ...............................................................................................  13
                           E. Duplication  of Federal Programs  .......................................................  13
                           F. Disclosure of Directed  Rule M akings  ..................................................  13


79-006